Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Colorectal Cancer Market Report Overview
The Colorectal Cancer (CRC) 15 (CGT and established/conventional therapies) market size was $18.9 billion in 2021. CRC has one of the largest gene therapy/oncolytic virus clinical pipelines across all of oncology, and a relatively active clinical cell therapy pipeline compared to other solid tumors. There are currently no marketed or Phase III CGT agents in CRC, reflecting the difficulties of progressing these drug types into the CRC market. This is largely due to insufficient efficacy; however, there is high clinical potential for a CGT agent that shows long-term disease control in metastatic CRC.
Colorectal Cancer Market Outlook, 2021-2031 ($ Billion)
For more insights into the Colorectal Cancer market forecast, download a free report sample
The Colorectal Cancer (CRC) market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by market for colorectal cancer (CRC).
Market Size (2021) | $18.9 billion |
Key Regions | APAC, Europe, Middle East, and North America |
Leading Companies | Turnstone Biologics Inc., Alaunos Therapeutics Inc, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Zhejiang Yangshengtang Biotech Co Ltd, Replimune Ltd, University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Iovance Biotherapeutics, and Transgene SA |
CRC Market Drivers
The key market drivers include-
- Combination therapy of OVs + ICIs in dMMR/MSI-H patients in 2L and 3L settings
- Suboptimal survival and lack of available treatment options for mCRC patients in 3L+ settings driving CGT usage
- Large eligible patient population sizes for cell therapies targeting EGFR
CRC Market- Unmet Needs
The unmet need for mCRC remains high, with the greatest unmet need within mCRC being the lack of treatment options for RAS-mutated patients, which make up a large proportion of the total mCRC patient population. Most patients with mCRC experience disease progression or develop resistance to the currently available treatment options, therefore the most clinically valuable way for CGT agents to add value is by demonstrating durable long-term remission. However, gene therapy and oncolytic viruses do not easily lend themselves to meeting this unmet need and may be more suitable to improving outcomes in dMMR/MSI-H patients due to these patients having more immunogenic tumors, and long-term data for patients treated with cell therapies remains to be generated.
CRC Market Segmentation by Region
The key regions in the CRC market are APAC, Europe, Middle East, and North America. In 2021, North America is the leading region in the CRC market. GlobalData expects that the North American thyroid function tests market will grow during the forecast period, primarily due to increases in the prevalence of hyperthyroidism and hypothyroidism, as well as greater public awareness of these diseases. Change in diet, lifestyle, and aging populations are driving the number of thyroid disease cases and thus test sales.
Colorectal Cancer Market Analysis by Region, 2021 (%)
For more regional insights into the Colorectal Cancer market, download a free report sample
CRC Market- Competitive Landscape and Future Players Based on Pipeline Strength
Some of the future players by number of ongoing clinical trials and development phase are Turnstone Biologics Inc., Alaunos Therapeutics Inc, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Zhejiang Yangshengtang Biotech Co Ltd, Replimune Ltd, University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Iovance Biotherapeutics, and Transgene SA. Many of the top 10 pharma companies are looking to enter the CGT space in CRC. The clinical pipeline for CGT agents in CRC is dispersed over many different companies, largely consisting of small-medium sized US or China-based biotechs and large global pharma companies. Cell therapy presents as the most advanced CGT modality, with three ongoing Phase II trials sponsored by Immunovative Therapies, Bristol-Myers Squibb, and ImmunityBio. Unlike in hematological malignancies, approvals based on Phase II data are highly unlikely in CRC, therefore the future players will be better elucidated when Phase III trials have been initiated.
Scope
This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by 8MM market.
Key Highlights
- Report deliverables include a PowerPoint report and an Excel-based forecast model
- Forecast includes 8 countries
- Forecast covers 2021-2031
- Seven markets are extrapolated, obtaining a 15-market value for all CRC therapeutics
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Alaunos Therapeutics
Replimune
Triumvira Immunologics
Table of Contents
Frequently asked questions
-
What was the CRC market size in 2021?
The CRC market size was $18.9 billion in 2021.
-
What are the key regions in the CRC market?
The key regions in the CRC market are APAC, Europe, Middle East, and North America.
-
Which is the greatest unmet need within the mCRC market?
The greatest unmet need within the mCRC market is the lack of treatment options for RAS-mutated patients.
-
Which are the leading companies in the CRC market?
Some of the leading companies in the CRC market are Turnstone Biologics Inc., Alaunos Therapeutics Inc, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Zhejiang Yangshengtang Biotech Co Ltd, Replimune Ltd, University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Iovance Biotherapeutics, and Transgene SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.